NUPREVIQ Trademark

Trademark Overview

On Friday, May 15, 2015, a trademark application was filed for NUPREVIQ with the United States Patent and Trademark Office. The USPTO has given the NUPREVIQ trademark a serial number of 79169811. The federal status of this trademark filing is SECTION 71 ACCEPTED as of Monday, July 11, 2022. This trademark is owned by Octapharma AG. The NUPREVIQ trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

Medical testing of patients for determining individual risk of forming inhibitors during a hemophilia treatment with factor VIII
nupreviq

General Information

Serial Number79169811
Word MarkNUPREVIQ
Filing DateFriday, May 15, 2015
Status706 - SECTION 71 ACCEPTED
Status DateMonday, July 11, 2022
Registration Number4872533
Registration DateTuesday, December 22, 2015
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 6, 2015

Trademark Statements

Pseudo MarkNU PREVIQ
Goods and ServicesMedical testing of patients for determining individual risk of forming inhibitors during a hemophilia treatment with factor VIII

Classification Information

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, August 6, 2015
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameOctapharma AG
Party Type30 - Original Registrant
Legal Entity Type25 - NOT AVAILABLE
AddressLachen 8853
CH
Party NameOctapharma AG
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCH
Party NameOctapharma AG
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCH

Trademark Events

Event DateEvent Description
Thursday, August 27, 2015ASSIGNED TO EXAMINER
Thursday, July 30, 2015SN ASSIGNED FOR SECT 66A APPL FROM IB
Thursday, August 6, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 11, 2015APPLICATION FILING RECEIPT MAILED
Tuesday, October 6, 2015PUBLISHED FOR OPPOSITION
Thursday, March 24, 2016FINAL DISPOSITION PROCESSED
Monday, August 31, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 16, 2015NOTICE OF PUBLICATION
Wednesday, September 16, 2015NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, September 16, 2015NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Thursday, September 24, 2015NEW REPRESENTATIVE AT IB RECEIVED
Friday, October 2, 2015NOTIFICATION PROCESSED BY IB
Tuesday, December 22, 2015REGISTERED-PRINCIPAL REGISTER
Thursday, January 21, 2016GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Friday, August 19, 2016NOTIFICATION PROCESSED BY IB
Thursday, March 24, 2016FINAL DISPOSITION NOTICE SENT TO IB
Thursday, August 11, 2016NEW REPRESENTATIVE AT IB RECEIVED
Thursday, August 11, 2016NEW REPRESENTATIVE AT IB RECEIVED
Thursday, August 18, 2016NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, December 21, 2021TEAS SECTION 71 RECEIVED
Monday, June 6, 2022CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, June 5, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, July 11, 2022REGISTERED-SEC.71 ACCEPTED
Monday, July 11, 2022NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Thursday, May 29, 2025INTERNATIONAL REGISTRATION RENEWED
Sunday, December 22, 2024COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Wednesday, June 5, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, June 5, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED

Related Keywords

nupreviq hemophilia during treatment factor viii inhibitors forming patients testing determining